Net sales grew 5% at constant currencies to USD 5.8 billion, led by biosimilars up 20% and now 33% of sales. Core EBITDA margin rose to 20.9%, while legal and restructuring costs weighed on IFRS net income. Full-year guidance is confirmed, with strong pipeline and new launches ahead.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.